Pulmonary fibrosis is a pulmonary interstitial disease characterized by scar tissue in the lungs resulting from many different conditions. In recent years, with an increasing number of drugs and environmental conditions studies have focused on drugs or chemical-induced pulmonary fibrosis. Some well-known substances such as paraquat, and in particular frequently used drugs can cause severe and often fatal pulmonary fibrosis in humans. These effects can also be demonstrated in laboratory animals. Up to now, nearly 150 chemical agents are considered related to the development of pulmonary fibrosis. Most significant among these include anticancer drugs (bleomycin, pingyangmycin, malilan, tamoxifen, carmustine, etc), cardiovascular drugs (amiodarone, angiotensin-converting enzyme inhibitor, etc), and anti-rheumatic drugs (e.g.methotrexate, leflunomide,).
Pulmonary fibrosis may eventually lead to respiratory failure and death. Treatment options are limited. Recently, two antifibrotic agents (pirfenidone and nintedanib) are approved for the treatment of IPF and recommended in international treatment guidelines. Unfortunately, both of them have not been shown sufficient antifibrotic activity to reverse the fibrotic progression. Due to the unclear pathogenesis of most drugs or environmentally related pulmonary fibrosis, there is still a lack of effective treatment measures. Therefore, prevention is of particular importance. The goal of this special edition Research Topic is to focus on the latest research progress about the pathogenesis of drug or poison-related pulmonary fibrosis. Another objective of this Special Issue noted related to some recent discoveries into new anti-fibrotic drugs, which may provide guidance for clinicians and effectively prevent patients from developing pulmonary fibrosis induced by various drugs or poisons.
All types of manuscripts, including Original Research, Review, Mini Review, and Case reports are of interest. The scope of the research topic mainly includes but is not limited to, the pathogenesis and prevention of pulmonary fibrosis induced by various drugs or poisons. Generally, the studies may include an investigation into:
• The combined use of network analysis, bioinformatics, and multi-omics to explore the pathogenesis of drug or poison-related pulmonary fibrosis.
• The molecular biological mechanisms of drug or poison-induced pulmonary fibrosis.
• The discovery of biologically active compounds and biomarkers for pulmonary fibrosis.
• The discovery and development of novel drugs for the prevention and/or treatment of pulmonary fibrosis.
Pulmonary fibrosis is a pulmonary interstitial disease characterized by scar tissue in the lungs resulting from many different conditions. In recent years, with an increasing number of drugs and environmental conditions studies have focused on drugs or chemical-induced pulmonary fibrosis. Some well-known substances such as paraquat, and in particular frequently used drugs can cause severe and often fatal pulmonary fibrosis in humans. These effects can also be demonstrated in laboratory animals. Up to now, nearly 150 chemical agents are considered related to the development of pulmonary fibrosis. Most significant among these include anticancer drugs (bleomycin, pingyangmycin, malilan, tamoxifen, carmustine, etc), cardiovascular drugs (amiodarone, angiotensin-converting enzyme inhibitor, etc), and anti-rheumatic drugs (e.g.methotrexate, leflunomide,).
Pulmonary fibrosis may eventually lead to respiratory failure and death. Treatment options are limited. Recently, two antifibrotic agents (pirfenidone and nintedanib) are approved for the treatment of IPF and recommended in international treatment guidelines. Unfortunately, both of them have not been shown sufficient antifibrotic activity to reverse the fibrotic progression. Due to the unclear pathogenesis of most drugs or environmentally related pulmonary fibrosis, there is still a lack of effective treatment measures. Therefore, prevention is of particular importance. The goal of this special edition Research Topic is to focus on the latest research progress about the pathogenesis of drug or poison-related pulmonary fibrosis. Another objective of this Special Issue noted related to some recent discoveries into new anti-fibrotic drugs, which may provide guidance for clinicians and effectively prevent patients from developing pulmonary fibrosis induced by various drugs or poisons.
All types of manuscripts, including Original Research, Review, Mini Review, and Case reports are of interest. The scope of the research topic mainly includes but is not limited to, the pathogenesis and prevention of pulmonary fibrosis induced by various drugs or poisons. Generally, the studies may include an investigation into:
• The combined use of network analysis, bioinformatics, and multi-omics to explore the pathogenesis of drug or poison-related pulmonary fibrosis.
• The molecular biological mechanisms of drug or poison-induced pulmonary fibrosis.
• The discovery of biologically active compounds and biomarkers for pulmonary fibrosis.
• The discovery and development of novel drugs for the prevention and/or treatment of pulmonary fibrosis.
